https://pharmadevicenews.com/what-does-nateras-leadership-change-mean-for-signatera-and-precision-oncology/ PharmaDeviceNews en 2026-11-06T17:28:21+00:00 What does Natera’s leadership change mean for Signatera and precision oncology? Latitude, Matthew Rabinowitz, Natera, Panorama, Prospera, Signatera, Signatera CDx, Solomon Moshkevich, Steve Chapman, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/nimbus-therapeutics-matches-established-arthritis-drugs-in-mice-but-can-sik2-inhibition-work-in-patients/ PharmaDeviceNews en 2026-11-06T17:25:22+00:00 Nimbus Therapeutics matches established arthritis drugs in mice, but can SIK2 inhibition work in patients? ACR Convergence 2026, American College of Rheumatology, Etanercept, Leon Collis, Nimbus Therapeutics, Peter Tummino, SIK2, Upadacitinib https://pharmadevicenews.com/wp-content/uploads/2026/06/cAMPfield-targets-ulcerative-colitis-and-Crohns-disease-with-a-selective-PDE4B-strategy-e1781934419210.webp https://pharmadevicenews.com/biocodexs-e15m-microbiome-investment-targets-a-major-drug-manufacturing-bottleneck/ PharmaDeviceNews en 2026-11-06T17:22:23+00:00 Biocodex’s €15m microbiome investment targets a major drug manufacturing bottleneck Beauvais, Biocodex, European Medicines Agency, France https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Generic-Image.webp https://pharmadevicenews.com/brii-bios-hepatitis-b-strategy-delivers-32-4-sustained-hbsag-loss-but-can-it-reach-phase-3/ PharmaDeviceNews en 2026-11-06T17:15:27+00:00 Brii Bio’s hepatitis B strategy delivers 32.4% sustained HBsAg loss, but can it reach Phase 3? American Association for the Study of Liver Diseases, Brii Biosciences Limited, BRII-179, David Margolis, elebsiran, ENHANCE, ENRICH, ENSURE, Jinlin Hou, National Medical Products Administration, Southern Medical University, Vir Biotechnology https://pharmadevicenews.com/wp-content/uploads/2026/08/Personalized-cancer-vaccines-explained-from-tumor-sequencing-to-a-bespoke-mRNA-treatment-e1787457158716.webp https://pharmadevicenews.com/could-16-weeks-of-ahb-137-change-hepatitis-b-treatment-ausperbio-reveals-15-month-durability/ PharmaDeviceNews en 2026-11-06T17:12:13+00:00 Could 16 weeks of AHB-137 change hepatitis B treatment? AusperBio reveals 15-month durability AB-10-8004, AB-10-8008, AHB-137, American Association for the Study of Liver Diseases, Ausper Biopharma, AusperBio Therapeutics, First Hospital of Jilin University, Jinlin Hou, Junqi Niu, Med-Oligo, Southern Medical University https://pharmadevicenews.com/wp-content/uploads/2026/07/Brii-Bios-hepatitis-B-breakthrough-faces-a-major-test-beyond-promising-HBsAg-loss-rates-e1783309497693.webp https://pharmadevicenews.com/antengenes-us1-2bn-ucb-deal-enters-human-testing-but-can-atg-201-control-autoimmune-disease/ PharmaDeviceNews en 2026-11-06T17:08:51+00:00 Antengene’s US$1.2bn UCB deal enters human testing, but can ATG-201 control autoimmune disease? AnTenGager, Antengene Corporation Limited, ATG-201, ATTRACT, National Medical Products Administration, Peking University People’s Hospital, Therapeutic Goods Administration, UCB, Zhanguo Li https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/gilead-sciences-livdelzi-achieves-75-alp-normalisation-response-in-phase-3-ideal-trial/ PharmaDeviceNews en 2026-11-06T17:04:00+00:00 Gilead Sciences’ Livdelzi achieves 75% ALP normalisation response in Phase 3 IDEAL trial American Association for the Study of Liver Diseases, American Gastroenterological Association, ASSURE, Cynthia Levy, Gilead Sciences, IDEAL, Ipsen, Journal of Hepatology, Livdelzi, RESPONSE, Seladelpar, Swati Tole, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/05/Zydus-moves-toward-a-PDUFA-decision-as-saroglitazar-enters-the-PBC-spotlight-e1779983251734.webp https://pharmadevicenews.com/vir-biotechnologys-eclipse-1-data-arrive-sunday-can-monthly-therapy-challenge-hepcludex/ PharmaDeviceNews en 2026-11-06T16:58:51+00:00 Vir Biotechnology’s ECLIPSE-1 data arrive Sunday. Can monthly therapy challenge Hepcludex? Alnylam Pharmaceuticals, American Association for the Study of Liver Diseases, Astellas Pharma, ECLIPSE-1, ECLIPSE-2, ECLIPSE-3, elebsiran, Gilead Sciences, Hepcludex, Marianne De Backer, Nancy Reau, Norgine, SOLSTICE, Tobevibart, Vir Biotechnology https://pharmadevicenews.com/wp-content/uploads/2026/08/AusperBio-tests-Au-HALO-liver-targeting-platform-with-AHB-171-clinical-study-1-e1785756571310.webp https://pharmadevicenews.com/ellipsis-health-buys-kouper-health-but-can-ai-finally-close-the-gaps-between-patient-visits/ PharmaDeviceNews en 2026-11-06T16:53:21+00:00 Ellipsis Health buys Kouper Health, but can AI finally close the gaps between patient visits? CVS Health Ventures, Ellipsis Health, General Catalyst, Kouper Health, Mainul Mondal, Sage, Salman Ali https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/fx-shoulder-solutions-brings-stemless-reverse-shoulder-replacement-to-the-us-but-is-the-evidence-ready/ PharmaDeviceNews en 2026-11-06T16:47:17+00:00 FX Shoulder Solutions brings stemless reverse shoulder replacement to the US, but is the evidence ready? Baptiste Martin, Easytech, Easytech Reversed, FX Shoulder Solutions, FX V135 Easytech Shoulder System, Howard W. Harris, Texas Orthopedic Specialists, US Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/11/FX-Shoulder-Solutions-announces-FDA-clearance-for-Easytech-Reversed-stemless-implant.webp https://pharmadevicenews.com/rybrevant-faspro-shrank-tumours-in-42-of-patients-but-can-johnson-johnson-prove-survival-benefit/ PharmaDeviceNews en 2026-11-06T16:42:28+00:00 Rybrevant Faspro shrank tumours in 42% of patients, but can Johnson & Johnson prove survival benefit? amivantamab, Barbara Burtness, Halozyme Therapeutics, Janssen Biotech, Johnson & Johnson, OrigAMI-4, OrigAMI-5, RYBREVANT FASPRO, US Food and Drug Administration, Yale Cancer Center https://pharmadevicenews.com/wp-content/uploads/2026/11/Johnson-Johnson-targets-second-line-head-and-neck-cancer-treatment-with-amivantamab.webp https://pharmadevicenews.com/ivonescimab-clears-half-of-lung-tumours-before-surgery-but-can-akeso-prove-lasting-benefit/ PharmaDeviceNews en 2026-11-06T16:37:37+00:00 Ivonescimab clears half of lung tumours before surgery, but can Akeso prove lasting benefit? Akeso, HARMONi-2, HARMONi-6, Ivonescimab, National Medical Products Administration, Nature Medicine, Summit Therapeutics, Tianjin Medical University Cancer Institute and Hospital https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-17-2026-09_15_56-AM-e1789616803290.webp https://pharmadevicenews.com/cleerlys-ai-can-quantify-coronary-plaque-can-530-patient-paramount-prove-it-changes-care/ PharmaDeviceNews en 2026-11-06T16:33:22+00:00 Cleerly’s AI can quantify coronary plaque. Can 530-patient PARAMOUNT prove it changes care? American Heart Association, Cleerly, Cleerly ISCHEMIA, Cleerly LABS, Cleerly PLAQUE, CONFIRM2, PARAMOUNT, Todd Villines, TRANSFORM, Udo Hoffmann, United States Food and Drug Administration, University of Virginia https://pharmadevicenews.com/wp-content/uploads/2026/05/Ribos-RBD1119-Phase-2-filing-puts-siRNA-antithrombotics-into-sharper-cardiovascular-focus-e1779979227353.webp https://pharmadevicenews.com/baycares-33m-proton-centre-fits-inside-a-conventional-radiation-vault-could-this-change-cancer-care-economics/ PharmaDeviceNews en 2026-11-06T16:29:04+00:00 BayCare’s $33m proton centre fits inside a conventional radiation vault. Could this change cancer care economics? BayCare Health System, BayCare Proton Center, Florida, John Greskovich, Leo Cancer Care, Marie, Mevion Medical Systems, MEVION S250-FIT, RaySearch Laboratories, RayStation, St. Joseph's Hospital, Stanford Medicine, Stephanie Conners, Tampa, Tina Yu https://pharmadevicenews.com/wp-content/uploads/2026/11/BayCare-begins-Mevion-S250-FIT-proton-therapy-at-33-million-Tampa-centre-e1793982504587.webp https://pharmadevicenews.com/carevalidate-promises-same-day-glp-1-delivery-but-can-it-solve-telehealths-last-mile-problem/ PharmaDeviceNews en 2026-11-06T16:25:00+00:00 CareValidate promises same-day GLP-1 delivery, but can it solve telehealth’s last-mile problem? CareValidate, Dallas, Houston, Jiten Chhabra, Tampa, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-tablets-generic-e1788149113473.webp https://pharmadevicenews.com/lynk-pharmaceuticals-advances-zemprocitinib-towards-china-approval-after-positive-phase-3-rheumatoid-arthritis-results/ PharmaDeviceNews en 2026-11-06T15:40:10+00:00 Lynk Pharmaceuticals advances zemprocitinib towards China approval after positive Phase 3 rheumatoid arthritis results Aik Goh, Center for Drug Evaluation, COURAGE-RA, LNK01001, Lynk Pharmaceuticals, National Medical Products Administration, Peking Union Medical College Hospital, Simcere Pharmaceutical Group, Xiaofeng Zeng, zemprocitinib, Zhao-Kui Wan https://pharmadevicenews.com/wp-content/uploads/2026/07/Chemomab-Therapeutics-and-Scipher-Medicine-merger-e1783686961263.webp https://pharmadevicenews.com/kos-biotechnology-partners-backs-fathom-therapeutics-us55m-ai-drug-discovery-financing/ PharmaDeviceNews en 2026-11-06T15:36:25+00:00 Kos Biotechnology Partners backs Fathom Therapeutics’ US$55m AI drug discovery financing Alex Tzoukas, Bret Williams, Fathom Therapeutics, Huafeng Xu, Jesús Izaguirre, Kos Biotechnology Partners, Kos BioVentures, Lilly Ventures, Microcosmos, Simos Simeonidis, Sutter Hill Ventures, Yujie Wu https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/bausch-health-presents-1630-patient-liver-disease-study-at-aasld-2026/ PharmaDeviceNews en 2026-11-06T15:27:09+00:00 Bausch Health presents 1,630-patient liver disease study at AASLD 2026 American Association for the Study of Liver Diseases, Anthony Jesudian, Bausch Health Companies Inc., Denver, Jonathan Sadeh, Salix Pharmaceuticals, The Liver Meeting 2026, Xifaxan https://pharmadevicenews.com/wp-content/uploads/2026/07/OrganOx-metra-partnership-tests-centralized-liver-perfusion-model-in-California-e1784877730272.webp https://pharmadevicenews.com/tandem-diabetes-cares-new-ceo-inherits-a-growing-1bn-business-can-she-deliver-profitability/ PharmaDeviceNews en 2026-11-06T15:15:28+00:00 Tandem Diabetes Care’s new CEO inherits a growing $1bn business. Can she deliver profitability? Abbott, Alcon, Beckie Robertson, Boston Scientific, Control-IQ+, FreeStyle Libre 3 Plus, GE HealthCare, Jeannette Bankes, John Sheridan, Merck, t:slim X2, Tandem Diabetes Care, Tandem Mobi https://pharmadevicenews.com/wp-content/uploads/2026/07/Par-Health-commercialises-approved-Janumet-XR-generic-after-patent-settlement-window-e1784901527496.webp https://pharmadevicenews.com/ul-solutions-studied-470-million-training-activities-are-pharma-workers-really-learning-their-sops/ PharmaDeviceNews en 2026-11-06T15:08:30+00:00 UL Solutions studied 470 million training activities. Are pharma workers really learning their SOPs? Association for GxP Excellence, ComplianceWire, UL Solutions, ULTRUS, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/thermo-fisher-scientifics-new-5bn-buyback-a-confidence-signal-or-capital-allocation-test/ PharmaDeviceNews en 2026-11-06T15:00:21+00:00 Thermo Fisher Scientific’s new $5bn buyback: A confidence signal or capital allocation test? Applied Biosystems, Clario Holdings, Marc Casper, Patheon, PPD, Thermo Fisher Scientific https://pharmadevicenews.com/wp-content/uploads/2026/05/Thermo-Fisher-Scientific-expands-mass-spectrometry-strategy-with-AI-enabled-analytics-e1780034139151.webp https://pharmadevicenews.com/bio-theras-bat2506-wins-a-china-first-but-can-it-challenge-johnson-johnsons-simponi/ PharmaDeviceNews en 2026-11-06T14:51:49+00:00 Bio-Thera’s BAT2506 wins a China first, but can it challenge Johnson & Johnson’s Simponi? Accord BioPharma, ASHULI, BAT2506, Bio-Thera Solutions, Dr. Reddy’s Laboratories, golimumab, Gotenfia, Immgolis, Immgolis Intri, Intas Pharmaceuticals, Johnson & Johnson, National Medical Products Administration, Shengfeng Li, Simponi, STADA Arzneimittel https://pharmadevicenews.com/wp-content/uploads/2026/07/Sail-Biomedicines-and-Johnson-Johnson-form-in-vivo-CAR-T-alliance-with-2.58bn-acquisition-option-e1785384287614.webp https://pharmadevicenews.com/stents-kidney-disease-and-heart-failure-ai-what-could-nyu-langones-aha-2026-data-reveal/ PharmaDeviceNews en 2026-11-06T14:47:45+00:00 Stents, kidney disease and heart failure AI: What could NYU Langone’s AHA 2026 data reveal? American Heart Association, Amrita Mukhopadhyay, BETTER CARE-HF, Harmony Reynolds, HARP, ISCHEMIA-CKD EXTEND, ISCHEMIA-EXTEND, Jeffrey Berger, Judith Hochman, NYU Langone Health, NYU Langone Heart, Sharine Wittkopp, Sripal Bangalore https://pharmadevicenews.com/wp-content/uploads/2026/08/Heart-failure-research-e1786393580679.webp https://pharmadevicenews.com/brc-therapeutics-hires-jazz-pharmaceuticals-veteran-but-can-its-cannabinoid-pipeline-deliver/ PharmaDeviceNews en 2026-11-06T14:44:27+00:00 BRC Therapeutics hires Jazz Pharmaceuticals veteran, but can its cannabinoid pipeline deliver? BRC Therapeutics, BRC-001, BRC-002, City of Hope, George Hodgin, Greenwich Biosciences, GW Pharmaceuticals, Jazz Pharmaceuticals, Justyna Kulpa, Kimberly Spancake, University of Colorado Anschutz, US Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/eli-lilly-brings-zepbound-and-foundayo-to-hims-hers-but-who-gains-most-from-the-deal/ PharmaDeviceNews en 2026-11-06T14:40:27+00:00 Eli Lilly brings Zepbound and Foundayo to Hims & Hers, but who gains most from the deal? Andrew Dudum, Eli Lilly and Company, Foundayo, Hims & Hers Health, Ilya Yuffa, LillyDirect, Novo Nordisk, orforglipron, tirzepatide, United States Food and Drug Administration, Wegovy, Zepbound https://pharmadevicenews.com/wp-content/uploads/2026/11/Eli-Lilly-expands-Foundayo-and-Zepbound-distribution-through-Hims-Hers-e1793975990967.webp https://pharmadevicenews.com/revelation-biosciences-sees-a-94bn-gemini-market-but-can-it-fund-the-clinical-test/ PharmaDeviceNews en 2026-11-06T14:35:50+00:00 Revelation Biosciences sees a $94bn Gemini market, but can it fund the clinical test? Avance Clinical, GEM-AKI, Gemini, James Rolke, Nasdaq, PRIME, Revelation Biosciences, TITAN, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/Revelation-Biosciences-builds-TITAN-trial-infrastructure-around-FDA-agreed-Gemini-development-pathway-e1787223770134.webp https://pharmadevicenews.com/maat-pharmas-picasso-trial-met-its-primary-goal-so-why-is-the-melanoma-efficacy-picture-still-uncertain/ PharmaDeviceNews en 2026-11-06T14:33:01+00:00 MaaT Pharma’s PICASSO trial met its primary goal, so why is the melanoma efficacy picture still uncertain? Assistance Publique Hôpitaux de Paris, European Investment Bank, European Medicines Agency, Gustave Roussy, Hervé Affagard, INRAE, MaaT Pharma, MaaT013, MaaT034, PICASSO, Xervyteg https://pharmadevicenews.com/wp-content/uploads/2026/03/MaaT-Pharma-tests-microbiome-therapy-limits-as-MaaT013-posts-pivotal-GI-aGvHD-data-e1774326349483.webp https://pharmadevicenews.com/servier-has-nine-glioma-abstracts-for-sno-2026-but-can-the-data-expand-its-treatment-reach/ PharmaDeviceNews en 2026-11-06T14:27:24+00:00 Servier has nine glioma abstracts for SNO 2026, but can the data expand its treatment reach? Day One Biopharmaceuticals, FIREFLY-1, FIREFLY-2, INDIGO, Ipsen, Ojemda, Servier, Servier Pharmaceuticals, Society for Neuro-Oncology, tovorafenib, US Food and Drug Administration, Voranigo, vorasidenib https://pharmadevicenews.com/wp-content/uploads/2026/05/Serviers-Day-One-deal-faces-its-first-major-oncology-proof-point-in-FIREFLY-2-e1778340631710.webp https://pharmadevicenews.com/onkos-surgical-expands-nanocept-again-but-can-antibacterial-implants-prove-their-clinical-value/ PharmaDeviceNews en 2026-11-06T14:22:21+00:00 Onkos Surgical expands NanoCept again, but can antibacterial implants prove their clinical value? ELEOS Limb Salvage System, Johannes Plate, NanoCept, Onkos Surgical, Patrick Treacy, University of Pittsburgh Medical Center, US Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/raidium-brings-stanfords-curtis-langlotz-on-board-but-can-its-ai-earn-radiologists-trust/ PharmaDeviceNews en 2026-11-06T14:18:46+00:00 Raidium brings Stanford’s Curtis Langlotz on board, but can its AI earn radiologists’ trust? American College of Radiology, Curia, Curtis Langlotz, Moffitt Cancer Center, Paul Hérent, Raidium, Raidium Read, Stanford AIMI, Stanford University https://pharmadevicenews.com/wp-content/uploads/2025/12/header-philips-verida-ct-angle-view-e1765695431687.avif https://pharmadevicenews.com/pulse-biosciences-plse-reports-86-thyroid-nodule-response-but-can-the-results-hold/ PharmaDeviceNews en 2026-11-06T13:45:40+00:00 Pulse Biosciences (PLSE) reports 86% thyroid nodule response, but can the results hold? American Thyroid Association, Clayman Thyroid Center, Kepal Patel, nPulse Vybrance Percutaneous Electrode System, NYU Langone Health, Paul LaViolette, PRECISE-BTN, Pulse Biosciences, Ralph Tufano, Sarasota Memorial Health Care System, Thomas Fahey, Weill Cornell Medicine https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-tablets-generic-e1788149113473.webp https://pharmadevicenews.com/network-bios-duke-university-deal-targets-a-critical-gap-in-medical-ai-what-happened-to-patients/ PharmaDeviceNews en 2026-11-06T13:41:42+00:00 Network Bio’s Duke University deal targets a critical gap in medical AI: What happened to patients? Asad Ali Ahmad, Duke Center for Precision Health, Duke University, Duke University School of Medicine, Mass General Brigham, Network Bio, NVIDIA, Raphael Potter, Svati H. Shah, University of Colorado Anschutz, University of Pennsylvania https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-research-lab.webp https://pharmadevicenews.com/fda-fast-track-for-frp-003-can-front-range-pharmaceuticals-tackle-long-covid-fatigue/ PharmaDeviceNews en 2026-11-06T13:38:10+00:00 FDA Fast Track for FRP-003: Can Front Range Pharmaceuticals tackle Long COVID fatigue? Front Range Pharmaceuticals, FRP-003, Isaac Foster, Long COVID, Suzanne Vernon, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/06/AMDIs-rapid-respiratory-panel-clears-the-FDA-as-point-of-care-PCR-competition-intensifies-e1781963612772.webp https://pharmadevicenews.com/ge-healthcare-backs-laza-medical-with-a-potential-160m-investment-but-can-robotic-ultrasound-transform-the-cath-lab/ PharmaDeviceNews en 2026-11-06T13:19:36+00:00 GE HealthCare backs LAZA Medical with a potential $160m investment, but can robotic ultrasound transform the cath lab? AMED, Amr Salahieh, Firas Zahr, GE HealthCare Technologies, Jyoti Gera, LAZA Medical, Los Gatos, Oregon Health & Science University, PA MedTech, Shifamed, Unorthodox Ventures https://pharmadevicenews.com/wp-content/uploads/2026/07/Dopl-Technologies-targets-FDA-clearance-for-remote-robotic-ultrasound-ecosystem-e1785175245650.webp https://pharmadevicenews.com/how-verismos-multi-chain-kir-car-platform-differs-from-conventional-car-t/ PharmaDeviceNews en 2026-11-06T13:15:09+00:00 How Verismo’s multi-chain KIR-CAR platform differs from conventional CAR-T American Society of Hematology, Brian Kim, CELESTIAL-301, Colorado Blood Cancer Institute, HLB Innovation, Michael Tees, SynKIR-310, Verismo Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/01/lymphoma-research.webp https://pharmadevicenews.com/emergent-biosolutions-wins-22-3m-biothrax-order-as-us-military-maintains-anthrax-preparedness/ PharmaDeviceNews en 2026-11-06T13:10:25+00:00 Emergent BioSolutions wins $22.3m BioThrax order as US military maintains anthrax preparedness Biomedical Advanced Research and Development Authority, BioThrax, CYFENDUS, Defense Health Agency, Emergent BioSolutions, Joe Papa, Paul Williams, United States Department of War https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/innovivas-antibiotics-are-growing-45-so-why-did-the-company-report-a-73-9m-loss/ PharmaDeviceNews en 2026-11-05T04:16:52+00:00 Innoviva’s antibiotics are growing 45%, so why did the company report a $73.9m loss? Armata Pharmaceuticals, Basilea Pharmaceutica, Entasis Therapeutics, GIAPREZA, GSK, Innoviva Inc., Innoviva Specialty Therapeutics, NUZOLVENCE, Pavel Raifeld, XACDURO, XERAVA, ZEVTERA https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/summit-therapeutics-has-2bn-from-astrazeneca-and-stronger-cancer-survival-data-but-will-the-fda-approve-ivonescimab/ PharmaDeviceNews en 2026-11-05T04:12:47+00:00 Summit Therapeutics has $2bn from AstraZeneca and stronger cancer survival data, but will the FDA approve ivonescimab? Akeso, AstraZeneca, Daiichi Sankyo, Datroway, HARMONi, HARMONi-2, HARMONi-3, HARMONi-7, Ivonescimab, Maky Zanganeh, Robert W. Duggan, Summit Therapeutics Inc. https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/evommune-bets-30m-on-a-vav1-degrader-that-could-challenge-jak-inhibitors-but-can-it-deliver-safer-autoimmune-treatment/ PharmaDeviceNews en 2026-11-05T04:08:47+00:00 Evommune bets $30m on a VAV1 degrader that could challenge JAK inhibitors, but can it deliver safer autoimmune treatment? EVO301, EVO570, EVO756, Evommune Inc., Greg Moss, HC118, Hinova Pharmaceuticals, Jeegar Patel, Yuanwei Chen https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/iadademstat-shows-95-response-rate-in-leukemia-as-oryzon-genomics-prepares-phase-3-development/ PharmaDeviceNews en 2026-11-04T22:01:01+00:00 Iadademstat shows 95% response rate in leukemia as Oryzon Genomics prepares Phase 3 development ALICE-2, ALICE-3, American Society of Hematology, FRIDA, iadademstat, Oryzon Genomics, U.S. National Cancer Institute https://pharmadevicenews.com/wp-content/uploads/2026/11/Leukemia-treatment-research-e1793829387870.webp